Evidence map›Paper›PMID 37652354›Full record

ArticleContemporary clinical trials2023

Integrative data analysis of clinical trials network studies to examine the impact of psychosocial treatments for black people who use cocaine: Study protocol.

Angela M Haeny, Caravella McCuistian, A Kathleen Burlew, Lesia M Ruglass, Adriana Espinosa, Ayana Jordan, Christopher Roundtree, Joel Lopez, Antonio A Morgan-López

Erratum issuedOpen access · greenAbstract readClinical Trial Protocol
In one paragraph

Article in Contemporary clinical trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Angela M HaenyDepartment of Psychiatry, Yale School of Medicine, United States of America.
Caravella McCuistianDepartment of Psychiatry and Behavioral Sciences, University of California San Francisco, United States of America. Electronic address: Caravella.Mccuistian@ucsf.edu.
A Kathleen BurlewDepartment of Psychology, University of Cincinnati, United States of America.
Lesia M RuglassDepartment of Psychology, The City College of New York and The Graduate Center, CUNY, United States of America.
Adriana EspinosaDepartment of Psychology, The City College of New York and The Graduate Center, CUNY, United States of America.
Ayana JordanDepartment of Psychiatry, Department of Population Health, NYU Grossman School of Medicine, United States of America.
Christopher RoundtreeDepartment of Psychology, University of Cincinnati, United States of America.
Joel LopezDepartment of Counseling and Clinical Psychology, Teachers College, Columbia University, United States of America.
Antonio A Morgan-LópezRTI International, United States of America.
University of Cincinnati · USCity College of New York · USColumbia University · USNew York University · USRTI International · USThe Graduate Center, CUNY · USUniversity of California, San Francisco · USYale University · US

Funding

The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
The Ohio Valley Node of the Clinical Trials Network (CTN-0153)UG1DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI T John WINHUSEN · 2015 to 2026
$42.5M
Western States Node of the National Drug Abuse Treatment Clinical Trials NetworkU10DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCARTY, DENNIS, SORENSEN, JAMES L · 2002 to 2015
$25.2M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Mentoring Emerging Scientists for Careers in Substance Use ResearchR25DA035163 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Carmen L Masson, Gideon St.Helen · 2014 to 2026
$4.6M
Integrated Safety Optimization Services for People Who Use Drugs In Targeted Areas Of High Overdose RatesR01DA057651 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Ayana Jordan · 2022 to 2026
$3.4M
Addressing health disparities by providing evidence-based treatment in the Black ChurchR01AA028778 · NIAAA · YALE UNIVERSITY · PI Ayana Jordan · 2020 to 2026
$3.2M
Culturally-responsive community-driven substance use recovery for Black and Latinx populationsU01DA060441 · NIDA · YALE UNIVERSITY · PI BELLAMY, CHYRELL DENISE, JORDAN, AYANA · 2023 to 2025
$2.7M
Meta-analysis of Individual Patient Data for PTSD/AODsR01AA025853 · NIAAA · RESEARCH TRIANGLE INSTITUTE · PI HIEN, DENISE AIMEE, MORGAN-LOPEZ, ANTONIO A · 2018 to 2021
$1.7M
Understanding Race-Related Stress as a Mechanism Associated with Alcohol Craving to Inform Culturally-Adapting Alcohol Treatment for Black AdultsK23AA028515 · NIAAA · YALE UNIVERSITY · PI HAENY, ANGELA MARIA · 2021 to 2025
$969k
NCATS NIH HHS UL1 TR001863NIAAA NIH HHS K23 AA028515NIAAA NIH HHS R01 AA025853NIAAA NIH HHS R01 AA028778NIDA NIH HHS L30 DA049246NIDA NIH HHS R01 DA057651NIDA NIH HHS R25 DA035163NIDA NIH HHS U01 DA060441NIDA NIH HHS U10 DA015815NIDA NIH HHS UG1 DA013732NIDA NIH HHS UG1 DA015815NIDA NIH HHS UG1 DA015831
6 · The paper itself

Abstract

backgroundCocaine overdose death rates among Black people are higher than that of any other racial/ethnic group, attributable to synthetic opioids in the cocaine supply. Understanding the most effective psychostimulant use treatment interventions for Black people is a high priority. While some interventions have proven effective for the general population, their comparative effectiveness among Black people remains unknown. To address this gap, our NIDA-funded Clinical Trials Network (CTN) study (0125), will use Integrative Data Analysis (IDA) to examine treatment effectiveness across 9 CTN studies. This manuscript describes the study protocol for CTN-0125.

methodsOf the 59 completed randomized clinical trials in the CTN with available datasets, nine met our inclusion criteria: 1) behavioral intervention, 2) targeted cocaine use or use disorder, 3) included sub-samples of participants who self-identified as Black and 4) included outcome measures of cocaine and psychostimulant use and consequences. We aim to 1) estimate scale scores of cocaine use severity while considering study-level measurement non-invariance, 2) compare the effectiveness of psychosocial treatments for psychostimulant use, and 3) explore individual (e.g., concomitant opioid use, age, sex, employment, pre-treatment psychiatric status) and study-level moderators (e.g., attendance/retention) to evaluate subgroup differences in treatment effectiveness.

conclusionThe NIDA CTN provides a unique collection of studies that can offer insight into what interventions are most efficacious for Black people. Findings from our CTN-0125 study have the potential to substantially inform treatment approaches specifically designed for Black people who use psychostimulants.

Indexed as

CocaineCocaine-Related DisordersPsychosocial InterventionBlack or African AmericanBlack PeopleHumansRandomized Controlled Trials as TopicTreatment OutcomeCocaineBlack/African AmericanComparative effectivenessIntegrated data analysisNIDA clinical trials networkStimulantsSubstance use treatment

Identifiers

PMID37652354
PMCPMC10635737
OpenAlexW4386247145

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.